Contact
Please use this form to send email to PR contact of this press release:
Celldex Therapeutics Initiates Global Phase 3 Program for Barzolvolimab in Patients with Chronic Spontaneous Urticaria
TO:
Please use this form to send email to PR contact of this press release:
Celldex Therapeutics Initiates Global Phase 3 Program for Barzolvolimab in Patients with Chronic Spontaneous Urticaria
TO: